Neurobiology of Aging
Volume 30, Issue 6 , Pages 864-874 , June 2009

Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging

  • Adele Woodhouse

      Affiliations

    • NeuroRepair Group, Menzies Research Institute, 43 Collins Street, Hobart, 7001 Tasmania, Australia
    • Corresponding Author InformationCorresponding author at: Private Bag 29, University of Tasmania, Hobart, 7001 Tasmania, Australia. Tel.: +61 3 62264834; fax: +61 3 62264833.
    • ,
  • James C. Vickers

      Affiliations

    • NeuroRepair Group, Menzies Research Institute, 43 Collins Street, Hobart, 7001 Tasmania, Australia
    • ,
  • Paul A. Adlard

      Affiliations

    • Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, 3052 Victoria, Australia
    • ,
  • Tracey C. Dickson

      Affiliations

    • NeuroRepair Group, Menzies Research Institute, 43 Collins Street, Hobart, 7001 Tasmania, Australia

Received 27 July 2007 ,Revised 29 August 2007 ,Accepted 5 September 2007.

References 

  1. Adlard PA, Vickers JC. Morphologically distinct plaque types differentially affect dendritic structure and organization in the early and late stages of Alzheimer's disease. Acta Neuropathol. 2002;103:377–383
  2. Akiyama H, Schwab C, Kondo H, Mori H, Kametani F, Ikeda K, et al. Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of β-amyloid protein. Neurosci. Lett. 1996;206:169–172
  3. Akiyama H, Hiroshi M, Saido T, Kondo H, Ikeda K, McGeer PL. Occurrence of the diffuse amyloid β-protein (Aβ) deposits with numerous Aβ-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia. 1999;25:324–331
  4. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 2004;24:4181–4186
  5. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, et al. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice. Exp. Neurol. 2003;184:247–263
  6. Borroni B, Premi E, Di Luca M, Padovani A. Combined biomarkers for early Alzheimer's disease diagnosis. Curr. Med. Chem. 2007;14:1171–1178
  7. Boutajangout A, Authelet M, Blanchard V, Touchet N, Tremp G, Pradier L, et al. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol. Dis. 2004;15:47–60
  8. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259
  9. Bussière T, Bard F, Barbour B, Grajeda H, Guido T, Khan K, et al. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am. J. Pathol. 2004;165:987–995
  10. Chishti MA, Yang D-S, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001;276:21562–21570
  11. Czech C, Tremp G, Pradier L. Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. Prog. Neurobiol. 2000;60:363–384
  12. Delatour B, Blanchard V, Pradier L, Duyckaerts C. Alzheimer pathology disorganized cortico-cortical circuitry: direct evidence from a transgenic animal model. Neurobiol. Dis. 2004;16:41–47
  13. De Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 2007;1097:114–145
  14. Dickson TC, King CE, McCormack GH, Vickers JC. Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease. Exp. Neurol. 1999;156:100–110
  15. Dickson TC, Adlard PA, Vickers JC. Sequence of cellular changes following localized axotomy to cortical neurons in glia-free cultures. J. Neurotrauma. 2000;17:1095–1103
  16. Dickson TC, Chuckowree JA, Chuah MI, West AK, Vickers JC. Novel Alzheimer's disease pathology reflects variable neuronal vulnerability and demonstrates the role of b-amyloid plaques in neurodegeneration. Neurobiol. Dis. 2005;18:286–295
  17. Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, et al. Inflammation occurs early during the Aβ deposition process in TgCRND8 mice. Neurobiol. Aging. 2004;25:861–871
  18. Evans J, Sumners C, Moore J, Huentelman MJ, Deng J, Gelband CH, et al. Characterization of mitotic neurons derived from adult rat hypothalamus and brain stem. J. Neurophysiol. 2002;87:1076–1085
  19. Ferrer I, Rovira MB, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 2004;14:11–20
  20. Higgins GA, Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav. Pharmacol. 2003;14:419–428
  21. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102
  22. Knowles RB, Gomez-Isla T, Hyman BT. Aβ associated neuropil changes: correlation with neuronal loss and dementia. J. Neuropathol. Exp. Neurol. 1998;57:1122–1130
  23. Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 2003;14:89–97
  24. Le RL, Cruz L, Urganc B, Knowles RB, Hsiao-Ashe K, Duff K, et al. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 2001;60:753–758
  25. Masliah E, Mallory M, Hansen L, Alford M, DeTeresa R, Terry R. An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer's disease. Am. J. Pathol. 1993;142:871–881
  26. Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J. Neuropathol. Exp. Neurol. 2001;60:357–368
  27. Matsunaga W, Miyata S, Hashimoto Y, Lin SH, Nakashima T, Kiyohara T, et al. Microtubule-associated protein-2 in the hypothalamo-neurohypophysial system: low-molecular-weight microtubule-associated protein-2 in pituitary astrocytes. Neuroscience. 1999;88:1289–1297
  28. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MHL, Phinney AL, et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006;12:801–808
  29. Mirra SS, Heyman A, McKeel D, Sumi SM, Brownlee LM, Vogel FS, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology. 1991;41:479–486
  30. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 2003;9:448–452
  31. Noda-Saita K, Terai K, Iwai A, Tsukamoto M, Shitaka Y, Kawabata S, et al. Exclusive association and simultaneous appearance of congophilic plaques and AT8-positive dystrophic neurites in Tg2576 mice suggest a mechanism of senile plaque formation and progression of neuritic dystrophy in Alzheimer's disease. Acta Neuropathol. 2004;108:435–442
  32. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321–332
  33. Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61:46–54
  34. Porzig R, Singer D, Hoffmann R. Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem. Biophys. Res. Commun. 2007;358:644–649
  35. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 1999;45:358–368
  36. Savage MJ, Iqbal M, Loh T, Trusko SP, Scott R, Siman R. Cathespin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the beta-amyloid precursor protein. Neuroscience. 1994;60:607–619
  37. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400
  38. Schwab C, Hosokawa M, McGeer PL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp. Neurol. 2004;188:52–64
  39. Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res. 1996;739:79–87
  40. Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer's disease. II. Progressive transformation and developmental sequence of dystrophic neurites. Acta Neuropathol. 1998;96:463–471
  41. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Prog. Neurobiol. 2000;60:139–165
  42. Woodhouse A, West AK, Chuckowree JA, Vickers JC, Dickson TC. Does β-amyloid plaque formation cause structural injury to neuronal processes?. Neurotox. Res. 2005;7:5–15

PII: S0197-4580(07)00373-9

doi: 10.1016/j.neurobiolaging.2007.09.003

Neurobiology of Aging
Volume 30, Issue 6 , Pages 864-874 , June 2009

Article Tools

* Image Usage & Resolution